Member Info for Fanti

I came across a German site

https://www.gmbhmakler.de/

Just wondering if sth similiar exists also in UK.

Would one know a marketplace or platform where one advertise the company is for sale?

Where to look a, please?

Replace development with research

.. Research keeping on despite more than critical finances and spend to expensive (outsourced) 3rdP.

I am just lost for words. Having had a loss of 3.5 M£ at YE2023 or end of June 2023 company expects to report an operating loss of £2.5 million (2022: £1.7 million) i.e. in a half period of time.

Development keeping on despite more than critical finances and spend to expensive (outsourced) 3rdP. The Bod just cannot stop wasting money instead of awaiting the results first but is unable to put any further expenditure on hold. If that is not disgusting.

Just double checked on investing.com again.

Where are the 392.979.724 shares are gone? Back to 70.261.878 outstanding shares as it was before. No money no shares? No clue.

Number of shares averaging 392,979,724 now.

Thats been in 2022 (already). My apologies mixing up times.

https://s3.eu-west-2.amazonaws.com/document-api-images-live.ch.gov.uk/docs/V2npWh16I8lJNzcXTl-csgni9NQih5CZLXVUowgXnxA/application-pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAWRGBDBV3JYERUZFL%2F20240220%2Feu-west-2%2Fs3%2Faws4_request&X-Amz-Date=20240220T141257Z&X-Amz-Expires=60&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEEQaCWV1LXdlc3QtMiJHMEUCIDTIg4ojEzy%2FRWkAP1oSa%2B2Z4Bt09mLNCTG0thepX0XzAiEAwsdNOqm9%2Bwd5vFq1rdx3TbsG6tjzSD9E8ZzdjbxPBPkquwUILRAFGgw0NDkyMjkwMzI4MjIiDLQ%2FKkbBpFJM8HGSbiqYBSBnHViwQVAaTthX0eaUcW%2FR95Fl6bwpcUGLSpFm0p%2FMM0rCsOaLQUfbTAsb0lKRGqppDnXnNCZoDbr9ehk0lZ6ZASxUD6tlQZNJ5MvE0kSAlsw%2FWtq5Pea%2BVxo%2BB0MfBzPE6IqMJpOMnRyPQYV5wHejl2qrzk%2BhpL0MxYptoESH6hQ3reYC9pG5V3R1NW%2Fr4KOyv8PxJKRNTkq208%2B62gcH1pVA69hnGitYS1U%2BtL2ud5RfcUEP9mA%2F%2BmfGo9datSXdFStOlKAi1qFs9BZsAGT7kNkjYCZ23L97tozbFe9NheK%2Bn13cfksIg6A2bX6aUQgvypW%2FJhTwk8tb8G3aazIGxEhEcbA29hSIeMW2dlPO4cnRXl1e%2FTtAP2dmprIKwauA8yeOA2p%2FzPkJmDgsuZVhMC3%2BTUVad8ajjz%2FbShCeU4w1fiwZtUSarirzIgIndQc7%2BANxt5Evb8%2Bmg1cbt8p%2BuR5uFSKd4VcqNItMGo4baLddOozg8MyzCxf08q6xZUbDfS03KJLaCvK4bG05adhl8eyJu1tmgKbY7OA5eTE4JUirzGr2c9mrYdHnTss3H3Lssz8rlUK25RxSo08d%2FGoyF0bA0BmcGmGmVTaARsNdcapDS2qmO0olkkinYekwjP4uMbmYpBMGseJDystRq8MfXmN5sLGq2D3PLVMX5VuL%2FigLXAzsZwb5QPfz%2BYJCKQrvv8PhZuvxjqC%2FE2tu1HAh7pjUaYARhFar1vR4Zcap8w2MmvFW2w4JPezv0aQ2i76A70VoGNLRdBUB4hANXE1ckZirdFEJe2jzLkerl0UjkAWivfBPRbNy98k%2BiU14GzcNx%2Bf97fWKNAcU5dL3eKPlo5mqr%2F571kD8kTrXmTCqjXyHrq4peZgwyJ7SrgY6sQHqyoGzz28WRjivxDKuDWjy1OTHvWIKUdyOn7nTssA%2FyTIzXy%2FS%2FtkCcpP%2FJwPkR5UIOFFuJuRS2JUHMGZTF37UjiNiKD1fnTXDlHImKdrcUrnHVotbETfiY5%2FmMq5d2Vd1mDOZf7CwwGGLynz2elpKB4v624P72uXW2PtAMEdi9DZjH3iEYLIj8VPnO9f2A674rCEIrbTNYMG9w73%2B0vJC8ybuus4jlCsCYrrijRLs2Os%3D&X-Amz-SignedHeaders=host&response-content-disposition=inline%3Bfilename%3D%22companies_house_document.pdf%22&X-Amz-Signature=55bde10e3a7661c6914fc65b0f888c851e61f44aade4173f974a7f4195f3ee81

.

Should such an action not have been RNSd? Though no DD on the market the company should have been authorised by us shareholders in general. Not sure if we have agreed.

I cannot believe the return of alotment of shares on 8th Aug 2023 worth GBP 842.708,62 announced 25th August reimbursed by the company. By coincidende may have taken place just in tome when the deal was made with Riverford and its cash provision to the company.

Great find opening eyes.

If wrong in my analysis I am pleased to being corrected.

I cannot believe the return of alotment of shares on 8th Aug 2013 worth GBP 842.708,62 announced 25th August reimbursed by the company. By coincidende may have taken place just in tome when the deal was made with Riverford and its cash provision to the company.

Great find opening eyes.

If wrong in my analysis I am pleased to being corrected.

In general, any invention or intellectual property is on the company behalf but of course this is is subject of negotiation. Dr Reader might be employed at Sareum Plc and is employed at its 100% subsidiary Sareum Ltd also. He possibly could be the owner of the latter also, we only can speculate.

https://suite.endole.co.uk/insight/people/9456642-dr-john-charles-reader

Sorry guys, bothering you. Do you run a business or know how to run a business?

Now is the time to mobilise succesful business and have mobilised reliable contracts and money till end of year when the results and the product pans out. Forward thinking paired with the will to be sucesaful.

Hi Potnak, I agree and know likewise about today's RNS reason, of course I take that in consideration. And I agree promotion mid trials is kind of funny if not unusual yet considering our current financials and business talks taking time, I find advertising and promotion the right thing to do.

BTW I have doubts scientists read financial papers. They may notice the results in a monthly newsletter generated by that australien institution, IMHO.

Well done :). Keep fingers crossed IR will give an answer.

Further Media and advertisements would also proof their commitment to run the business long term and not to get 1801 into trials only. But that are my concerns only.

Text like

Hi Pharma Guys, be prepared that we are ready with Trial 1801 in due course followed up for Ph2 by end of this year targeting bla bla Psoriasis market (sorry, no expert). We are open for business. Don't hesitate to contact us. Looking forward to hearing from you.

Is it wishful thinking them to take their chance in promoting the progress the compounds and appetite for a successful business in the near future? It must not all be discussed in secret in a hidden bar or at an symposium, doesn't it?

The good news was published today on the financial markets (Alliance News and sharecast. com). Still awaiting the final results I yet would target Pharma magazines also to remind on our compounds once again and recruit potential licensees, partner or investors, also.

Does this makes sense and can be expected to come forward with?

I am pleased they delivered some detail as to where we stand right now.

Great find HBD.

2024-01-30

Publication of JP2024012649A

Inventor translated are:

languages ​​English Inventor Andrew Hassig Christian William Strauss Brian James Hansen Ryan Lynn Anderes Kenamiltinovik Snezanajay. You Angie Krenke Barbara Kowalski Mark

I do care. With a pinch of salt I acknowledge the BOD could earmark February for the drawdown of 1,4M with RF, yet is awaiting trial results two month later in QII, indeed.

Also, what was the BOD thinking when they agreed to these weird and foreseeable suicidal terms?

They should have had consulted us investors beforehand but obviously follow their own agenda.

Sorry, should have said 0,3M, of course.